Severe hyperglycemia during renally adjusted gatifloxacin therapy

被引:14
作者
Blommel, AL [1 ]
Lutes, RA [1 ]
机构
[1] Monongahela Valley Hosp, Dept Nephrol, Monongahela, PA USA
关键词
gatifloxacin; hyperglycemia;
D O I
10.1345/aph.1E679
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of severe hyperglycemia in a nondiabetic patient receiving gatifloxacin that was properly dosed based on renal function. CASE SUMMARY: A 65-year-old nondiabetic female with progressive renal dysfunction was admitted for severe hyperglycemia. The patient had received 9 days of a 10-day course of renally adjusted therapy with gatifloxacin 200 mg/day for bronchitis. Her blood glucose level on admission was 1121 mg/dL, at which point the gatifloxacin was discontinued. After several days of intensive insulin therapy, the blood glucose levels returned to normal, and the patient was subsequently discharged. DISCUSSION: Gatifloxacin-induced hyperglycemia has been reported in the literature, but based on a MEDLINE search (1966-December 2004), no such cases were found in a nondiabetic patient receiving the proper gatifloxacin dose, adjusted for degree of renal insufficiency. The available case reports seem to suggest the increase in blood glucose concentrations could have been precipitated by high drug concentrations in patients not receiving the renally adjusted dose or in those with preexisting, undiagnosed diabetes. A definite mechanism of action for gatifloxacin-induced hyperglycemia is not known. The Naranjo probability scale revealed a probable adverse reaction of hyperglycemia associated with gatifloxacin therapy. CONCLUSIONS: Healthcare professionals should be more aware of the possible development of hyperglycemia in all patients taking gatifloxacin, including those who are not diabetic and those receiving appropriately reduced doses for renal dysfunction.
引用
收藏
页码:1349 / 1352
页数:4
相关论文
共 17 条
[1]  
*ABBB LAB, 1999, PACK INS FUR
[2]   Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction [J].
Ambrose, PG ;
Bhavnani, SM ;
Cirincione, BB ;
Piedmonte, M ;
Grasela, TH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :435-440
[3]  
Arce Francis Clifford A, 2004, Endocr Pract, V10, P40
[4]   Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients [J].
Biggs, WS .
JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, 2003, 16 (05) :455-457
[5]  
*BRIST MEYERS SQUI, PACK INS TEQ GAT
[6]   Possible gatifloxacin-induced hyperglycemia [J].
Donaldson, AR ;
Vandiver, JR ;
Finch, CK .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (04) :602-605
[7]   A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men [J].
Gajjar, DA ;
LaCreta, FP ;
Uderman, HD ;
Kollia, GD ;
Duncan, G ;
Birkhofer, MJ ;
Grasela, DM .
PHARMACOTHERAPY, 2000, 20 (06) :49S-58S
[8]   Clinical pharmacology of gatifloxacin, a new fluoroquinolone [J].
Grasela, DM .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S51-S58
[9]   Gatifloxacin-induced hyperglycemia [J].
Happe, MR ;
Mulhall, BP ;
Maydonovitch, CL ;
Holtzmuller, KC .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (12) :968-969
[10]   AMIODARONE THERAPY AND GLUCOSE-TOLERANCE - A PROSPECTIVE TRIAL [J].
LAKHDAR, AA ;
FARISH, E ;
DUNN, FG ;
HILLIS, WS .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (06) :651-652